Xuxi Zhang

IG(MedDiet+Nuts): 1142 CG:1190 HbA1c (%): ‐  Blood pressure (mm Hg): Systolic:  ‐  Diastolic:  ‐  Total Cholesterol (mg/dl): LDL:  ‐  HDL: 50.0(43.0, 59.0)/49.6(42.2,58.2) BMI: 29.8±3.8/29.5±3.9 Without diabetic retinopathy (%):100 Blood pressure (mm Hg): Systolic:  ‐  Diastolic:  ‐  Total Cholesterol (mg/dl): LDL:  ‐  HDL: 50.0(40.0, 59.1) BMI: 30.2±4.3 Without diabetic retinopathy (%):100 supplemented with mixed nuts (MedDiet+Nuts) vs. Low ‐ fact control diet UKPDS 69, 2004 Baseline IG: 758 CG: 390 Follow ‐ up (7.5 years) IG: 300 CG: 152 Patients with type 2 diabetes Female (%): 46 Mean age: 56.4±8.1 Duration of diabetes (interquartile range, year): 2.7(1.0 ‐ 4.2) HbA1c (%):6.9±1.7 Blood pressure (mm Hg): Systolic: 159±20 Diastolic: 94±10 Total Cholesterol (mmol/l): LDL: 3.6±1.1 HDL: 1.10±0.27 BMI: 29.8±5.5 Without diabetic retinopathy (%): 81.4 Patients with type 2 diabetes Female (%): 42 Mean age: 56.5±8.1 Duration of diabetes (interquartile range, year): 2.5(1.0 ‐ 4.4) HbA1c (%): 6.8±1.5 Blood pressure (mm Hg): Systolic: 160±18 Diastolic: 94±9 Total Cholesterol (mmol/l): LDL: 3.6±1.1 HDL: 1.10±0.28 BMI: 29.3±5.5 Without diabetic retinopathy (%): 80 RCT England Blood ‐ pressure ‐ control intervention Tight control of blood pressure (aim<150/85mm Hg) vs. Less tight control of blood pressure (aim< 180/105 mmHg) VADT, 2016 Baseline and follow ‐ up (5 years) & : IG: 433 CG: 425 Veterans with Type 2 Diabetes Female (%): 3.7 Mean age: 60±8 Duration of diabetes (year): 11.5±7.8 HbA1c (%):9.3±1.4 Blood pressure (mm Hg): Systolic: 132±17 Diastolic: 76±10 Total Cholesterol (mmol/l): LDL: 2.8±0.83 HDL: 0.93±0.23 BMI: 32±4 Without diabetic retinopathy (%): ‐  Veterans with Type 2 Diabetes Female (%): 3.1 Mean age: 60±8 Duration of diabetes (year): 11.5±6.6 HbA1c (%):9.4±1.5 Blood pressure (mm Hg): Systolic: 131±17 Diastolic: 76±10 Total Cholesterol (mmol/l): LDL: 2.8±0.86 HDL: 0.93±0.28BMI: 31±4 Without diabetic retinopathy (%): ‐  RCT USA Glycemic ‐ control intervention Intensive glucose control (started on maximal dose) vs. Standard control (started on half the maximal dose) 7 185 Prevention and control of diabetic retinopathy